Combination therapy in the management of complex dyslipidemias

Current Opinion in Lipidology

Volumn 15, Issue 4, 2004, Pages 423-431

  Davidson, Michael H ^a   Toth, Peter P ^b,c  

^a RUSH MEDICAL COLLEGE   (United States)

^b Sterling Rock Falls Clinic ^*  (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Atherosclerosis; Ezetimibe; Fibrate; Hepatotoxicity; Lipoprotein; Metabolic syndrome; Myopathy; Niacin; Rhabdomyolysis; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; COLESEVELAM; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION;

ALGORITHMS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEINS; NIACIN;

EID: 4043142924     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000137221.16160.b9     Document Type: Review

References (63)

1. Foeber JC, Frohlich JJ, Gerest JJ, et al. Recommendations for the management and treatment of dyslipidemia. Report of the working group on hypercholesterolemia and other dyslipidemias. CMAJ 2000; 162:1441-7.
2. Sloan KL, Sales AE, Willems JP, et al. Frequency of serum low-density cholesterol measurement and frequency of results ≤ 100 mg/dL among patients who had coronary events (Northwest VA Network Study). Am J Cardiol 2001; 88:1143-1146.
3. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071-1080. This is an important study which utilized intravascular ultrasonography to demonstrate that aggressive LDL reduction to a mean level of 79 mg/dl resulted in plaque stabilization, whereas less-aggressive LDL reduction to a mean level of 111 mg/dl was associated with plaque progression.
4. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infection 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504. Epub 2004 Mar 08. This paper details the results of the Pravastatin or Atorvastatin Evaluation and Infection Therapy Trial, a landmark trial which showed that aggressive LDL reduction to a mean of 63 mg/dl improved coronary outcomes and mortality significantly better than less-aggressive LDL reduction to 95 mg/dl.
5. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 1993; 269:3002-3008.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287:356-359.
7. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
9. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40:2125-2134.
10. Ballantyne C, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 19:e9043-e9044.
11. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91:418-424.
12. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 8:685-689.
13. Gagné C, Bays HE, Weiss SR, et al. Efficay and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90:1084-1091.
14. Sager PT, Melani L, Lipka L, et al. Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003; 92:1414-1418. This study demonstrated that ezetimibe used in combination with statins provides significant additional reductions in serum C-reactive protein levels in comparison with statin therapy alone.
15. Zetia [prescribing information]. North Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2002.
16. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54:309-319.
17. Tolleshaug H, Hobgood KK, Brown MS, et al. The LDL receptor locus in familial hypercholesterolemia: multiple mutations disrupt transport and processing of a membrane receptor. Cell 1983; 32:941-951.
18. Glueck CJ, Spiers J, Tracy T, et al. Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism 1991; 40:842-848.
19. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Amer Coll Cardiol 2002; 40:568-573.
20. Gebhard RL, Ewing SL, Schlasner LA, et al. Effect of 3-hydroxy-3-methyl coenzyme. A reductase inhibition on human gut mucosa. Lipids 1991; 26:492-494.
21. Di Mauro S, Bonilla E, Davidson M, et al. Mitochondria in neuromuscular disorders. Biochem Biophys Acta 1998; 1366:199-210.
22. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatments in humans. Clin Pharmacol Ther 1995; 57:62-66.
23. Simvastatin. Physician's desk reference. MontVale, NJ: Medical Economics Company; 2002.
24. Isaacsohn J, Black D, Troendle A, Orloff D. The impact of the National Cholesterol Education Program Adult Treatment Panel III guidelines on drug development. Am J Cardiol 2002; 89 (Suppl):45C-49C.
25. Davidson MH. Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep 2000; 2:14-19.
26. Dujovne CA, Ettinger MP, McNeer JF, et al. for the Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90:1092-1097.
27. Davidson MH, McGarry T, Bettis R, et al. on behalf of the Ezetimibe Study Group. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40:2125-2134.
28. Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin [abstract]. Atherosclerosis 2000; 151:135.
29. Davidson MH, Dicklin MR, Maki KC, Kleinpell RM. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs 2000; 9:2663-2671.
30. Bradford RH, Shear CL, Chermos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolaemia. Arch Intern Med 1991; 151:43-49.
31. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 257:38-42.
32. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68:122-129.
33. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84:413-428.
34. Pravastatin. Physician's desk reference. MontVale, NJ: Medical Economics Company; 2002.
35. Davidson MH. Controversy surrounding the safety of cerivastatin. Exp Opin Drug Saf 2002; 1:207-212.
36. Davidson MH. Rosuvastastin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs 2002; 11:125-141.
37. Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76:80A-83A.
38. Pan WJ, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000; 40:316-323.
39. Herman RJ. Drug Interactions and the statins. CMAJ 1999; 161:1281-1286.
40. Wen X, Wang JS, Backman JT, et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001; 29:1359-1361.
41. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301:1042-1051.
42. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol 2002; 13:415-420.
43. Gupta EK, Ito MK. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis 2002; 4:124-137.
44. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109:597-598.
45. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271:672-677.
46. Data on file. Whitehouse Station, NJ: Merck/Schering-Plough Pharmaceuticals; 2002.
47. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85:37-45.
48. Athyros VG, Papageorgiou AA, Kontopoulos AG. Statin-fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis 2001; 155:263-264.
49. Pauciullo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvstatin and bezafibrate in patients with mixed hyperlipidaemia (FACT Study). Atherosclerosis 2000; 150:429-436.
50. Farnier M, Bortolini M, Salko T. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfbrozil). Am J Cardiol 2003; 91:238-240.
51. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94:13-20.
52. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81:60B-65B.
53. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71-75.
54. Hanston PD, Horn JR. Drug interactions with HMG CoA reductase inhibitors. Drug Interactions Newsletter 1998; 103-106.
55. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81:60B-65B.
56. Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994; 74:499-500.
57. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMB-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999; 138:151-155.
58. Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999; 22:25-28.
59. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35:1096-1107.
60. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
61. Davidson MH, Toth PP. The treatment of dyslipidemias with statins, ezetimibe, fibrates, and niacin. Prog Cardiovasc Dis 2004; 46.
62. Brown, BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
63. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA 2000; 284:1263-1270.